NDA 017849 · Ani Pharms
Brethine
Terbutaline Sulfate · Oral
Last checked: Nov 20, 2026Latest source record: Apr 8, 2011 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1976
May 17, 1976
Approved uses
1
Original approval plus efficacy supplements
Registered trials
52
22 Phase 3, 4 recruiting
FAERS reports
1,839
1,762 serious, 169 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: TOCOYSIS Oral terbutaline sulfate has not been approved for and should not be used for acute or maintenance tocolysis. In particular, terbutaline sulfate should not be used for maintenance tocolysis in the outpatient or home setting. During pregnancy, serious adverse reactions, including death, have been reported after administration of terbutaline sulfate to pregnant women. In the mother, these adverse reactions include increased heart rate, transient hyperglycemia, hypokalemia, cardiac arrhythmias, pulmonary edema and myocardial ischemia. Increased fetal heart rate and neonatal hypoglycemia may occur as a result of maternal administration. [See Contraindications-Tocolysis ]
What it is approved for
From the label in effect Nov 15, 2019.
INDICATIONS AND USAGE Terbutaline Sulfate Tablets USP are indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 17, 1976 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
- BRETHINE · TERBUTALINE SULFATE 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued · TE AB
- BRETHINE · TERBUTALINE SULFATE 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Terbutaline" as an intervention, any sponsor and status, largest first.
- A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With AsthmaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02224157 · 4,215 participants · Start Nov 28, 2014 · Primary completion Aug 16, 2017
Drug: budesonide/formoterol 'as needed' + budesonide placebo bid; budesonode bid + terbutaline 'as needed' · For: Asthma
Sites: Sydney, Australia; Botucatu, Brazil; Florianópolis, Brazil · 340 sites in all
- A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02149199 · 3,850 participants · Start Jul 7, 2014 · Primary completion Aug 2, 2017
Drug: budesonide/formoterol 'as needed' + budesonide placebo bid; terbutaline 'as needed' + placebo budesonide bid and 1 more · For: Asthma
Sites: Bedford Park, Australia; Concord, Australia; Maroubra, Australia · 255 sites in all
- Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mgPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00242775 · 2,100 participants · Start May 2005
Drug: Budesonide/formoterol Turbuhaler; Salmeterol/fluticasone Diskus · For: Asthma
Sites: Mar del Plata, Argentina; Monte Grande, Argentina; Córdoba, Argentina · 143 sites in all
- Study to Investigate the Efficacy of Symbicort® SMART.Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00839800 · 2,091 participants · Start Feb 2009 · Primary completion Feb 2011
Drug: Symbicort Turbuhaler; Terbutaline Turbuhaler · For: Asthma
Sites: Buenos Aires, Argentina; Capital Federal, Argentina; Mar del Plata, Argentina · 109 sites in all
- SHARE - Symbicort and Health Economics in a Real Life EvaluationPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00259766 · 1,970 participants · Start Apr 2004
Drug: Budesonide; Formoterol and 1 more · For: Asthma
Sites: Alingsås, Sweden; Angered, Sweden; Arlöv, Sweden · 108 sites in all
- DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in AdultsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00252863 · 1,600 participants · Start Dec 2004
Drug: Symbicort, used twice daily (b.i.d) and as needed (prn); Budesonide Turbuhaler 200 µg and 11 more · For: Asthma
Sites: Stuttgart, Germany; München, Germany; Cottbus, Germany · 169 sites in all
- Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate AsthmaPivotal-lookingCompleted
Università degli Studi di FerraraAcademic, hospital or other
NCT00849095 · 860 participants · Start Apr 2009 · Primary completion Apr 2013
Drug: budesonide/formoterol combination (PRN); budesonide/formoterol combination and 2 more · For: Asthma
Sites: Ancona, Italy; Cassano delle Murge, Italy; Benevento, Italy · 31 sites in all
- Prevention of Asthma Relapse After Discharge From EmergencyPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00326053 · 600 participants (planned) · Start May 2006
Drug: Budesonide/formoterol · For: Asthma
Sites: Calgary, Canada; Edmonton, Canada; Lethbridge, Canada · 20 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea426
- asthma380
- wheezing258
- pneumonia209
- cough206
- drug ineffective153
- fatigue148
- loss of personal independence in daily activities142
- therapeutic product effect incomplete124
- sleep disorder due to a general medical condition120
- nasopharyngitis112
- malaise108
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 63 |
| 2005 | 57 |
| 2006 | 51 |
| 2007 | 83 |
| 2008 | 77 |
| 2009 | 81 |
| 2010 | 77 |
| 2011 | 59 |
| 2012 | 18 |
| 2013 | 31 |
| 2014 | 28 |
| 2015 | 32 |
| 2016 | 25 |
| 2017 | 49 |
| 2018 | 54 |
| 2019 | 111 |
| 2020 | 149 |
| 2021 | 183 |
| 2022 | 189 |
| 2023 | 138 |
| 2024 | 119 |
| 2025 | 87 |
| 2026 | 78 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma.
O'Byrne PM, FitzGerald JM, Bateman ED, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Comparative Study
- Intravenous Bronchodilators in Pediatric Critical Asthma: A Systematic Review and Network Meta-Analysis.
Abu-Sultaneh S, Miller AG, Basnet S, et al. · Pediatr Pulmonol 2025 · Systematic Review, Network Meta-Analysis
- Clinical pharmacokinetics of terbutaline in humans: a systematic review.
Sultan K, Zamir A, Ashraf W, et al. · Naunyn Schmiedebergs Arch Pharmacol 2023 · Systematic Review
- Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial.
Hardy J, Baggott C, Fingleton J, et al. · Lancet 2019 · Multicenter Study, Randomized Controlled Trial
- Fenoterol in asthma.
Anderson G, Wilkins E, Jariwalla AG · Br J Dis Chest 1979 · Clinical Trial, Comparative Study
- Nebuhaler technique.
Gleeson JG, Price JF · Br J Dis Chest 1988 · Clinical Trial, Controlled Clinical Trial
Sponsor: Ani Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.